Precision BioSciences to Present Late-Breaking Hepatitis B Gene Editing Data
Precision BioSciences, Inc. (DTIL) has been selected to deliver a late-breaking oral presentation on its investigational hepatitis B therapy, PBGENE-HBV, at the American Association for the Study of Liver Diseases annual meeting in Denver, Colorado. The presentation is scheduled for November 8, 2026, and will focus on data showing durable pregenomic RNA loss in chronic hepatitis B patients.
The therapy, which is currently being evaluated in a global Phase 1 trial called ELIMINATE-B, is designed to eliminate covalently closed circular DNA, the sole source of viral replication. By targeting and removing this viral DNA, the gene editing candidate aims to provide a functional cure for chronic hepatitis B, a condition that currently lacks a curative treatment and increases the risk of liver cancer or cirrhosis.
Moving forward, the company is continuing to enroll patients in its ongoing trial across the United States, Europe, Asia, and Oceania. The upcoming presentation will provide key clinical insights into the safety and effectiveness of the candidate, as well as the potential of its repeat lipid nanoparticle delivery method to achieve a viral cure.
Key points
- Precision BioSciences (DTIL) will deliver an oral presentation on its hepatitis B candidate, PBGENE-HBV, on November 8, 2026.
- The presentation will highlight durable pregenomic RNA loss in both HBeAg positive and negative chronic hepatitis B patients.
- PBGENE-HBV is designed to eliminate covalently closed circular DNA, the primary source of viral replication.
- The global Phase 1 trial is currently enrolling patients across multiple regions to determine optimal dosing.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is PBGENE-HBV?
PBGENE-HBV is an investigational in vivo gene editing therapy being developed by Precision BioSciences as a potential curative treatment for chronic hepatitis B.
When will Precision BioSciences present its clinical data?
The company will deliver a late-breaking oral presentation at the AASLD Liver Meeting on Sunday, November 8, 2026, in Denver, Colorado.
How does PBGENE-HBV differ from current hepatitis B treatments?
Unlike current therapies that rarely achieve a cure, PBGENE-HBV targets and eliminates covalently closed circular DNA, which is the sole source of replication for the hepatitis B virus.